Ventyx Biosciences to Host R&D Event on January 26, 2023
ENCINITAS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on...
Pharmaceutical
Intercept Pharmaceuticals to Present at J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023
MORRISTOWN, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development...
Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield Contract
Total Procurement-related Revenue Recognition of $38.1 Million to Paratek in December 2022Procurement Triggered by Positive Top-Line Data from Pilot Efficacy...
Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced
New round of financing led by Vensana Capital will support technology platform expansion and further validating VX1, Volta’s Artificial Intelligence...
AUM Biosciences Receives U.S. FDA Rare Pediatric Disease Designation for AUM302 for Treatment of Neuroblastoma
AUM302 is potentially eligible to receive a rare pediatric disease priority review voucher at the time of marketing approvalSINGAPORE and...
MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
CARMEL, Ind., Jan. 05, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™...
Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders
Expands intellectual property portfolio with composition-of-matter patent protection for second novel molecular glue Protein degrader intellectual property portfolio now includes...
Orion and Amneal enter strategic partnership – Orion receives exclusive licence to commercialise Amneal’s generic products in Europe, Australia and New Zealand
ORION CORPORATION PRESS RELEASE 4 JANUARY 2023 at 16.00 EET Orion and Amneal enter strategic partnership – Orion receives exclusive...
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (COVALENT-111) Study of BMF-219
COVALENT-111, now underway in the US, has completed Phase I and is currently enrolling type 2 diabetes patients in the Phase...
Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023
MORRISTOWN, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development...
Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company...
Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference
Dyadic's executive management to attend the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and...
Ceapro Announces Grant of Stock Options
EDMONTON, Alberta, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage...
Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV
Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV in The Oncologist Lugano,...
Elixirgen Therapeutics to Attend the 2023 Biotech Showcase Conference
BALTIMORE, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and...
Tenax Therapeutics Announces Reverse Stock Split
MORRISVILLE, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying,...
Collegium Provides 2023 Financial Guidance
– Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million – – Adjusted Operating Expenses* Expected...
Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors
CHARLOTTESVILLE, Va. and CARMEL, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”),...
Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer
SYDNEY, AUSTRALIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage...
Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States
Dr. Susana Banerjee (The Royal Marsden NHS Foundation Trust, UK), will be the ENGOT and Global Clinical Trial Lead Dr. Shannon...